Quartier P, Alexeeva E, Tamas C, et al. - In this study, the efficacy and safety of two canakinumab monotherapy tapering regimens were analyzed to maintain complete clinical remission (CR) in children with systemic juvenile idiopathic arthritis (sJIA). Researchers designed a two‐part open‐label study [in Part I, individuals received 4 mg/kg canakinumab subcutaneously every 4 weeks (q4w) and discontinued glucocorticoids and/or methotrexate as appropriate)]. A total of 182 individuals were included in Part I of the study and 75 were assigned randomly in Part II. The data demonstrated that in patients with sJIA, reduction of exposure to canakinumab may be beneficial who achieved CR, but consistent IL‐1 inhibition seems necessary to maintain this response.